The strong Phase 2 data significantly de-risks ABCL635 and supports best-in-class positioning. Traders should monitor for Phase 3 initiation, additional data at medical conferences later this year, and regulatory interactions. The stock may re-rate upward given the large unmet need and potential to capture share from approved NK3R small molecules.
Drug in focus
ABCL drug pipeline →ABCL635
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
- Next catalyst
- None dated
What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $9.34entry
- T+1 · 3mo ago +4.50%α +4.82% · $9.76
- T+5 · 3mo ago +19.91%α +19.96% · $11.20
- T+20 · 2mo ago +22.48%α +23.40% · $11.44
- T+60 · 14d ago +30.41%α +32.82% · $12.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbCellera announced positive top-line Phase 2 results for ABCL635, an NK3R antagonist antibody for moderate-to-severe vasomotor symptoms (hot flashes). The single 600 mg subcutaneous dose met primary endpoints with statistically significant reductions in VMS frequency (83% vs 33% placebo, p<0.001) and severity (58% vs 12% placebo, p<0.001) at week 4, with a favorable safety profile (no SAEs or severe AEs in the treatment group). The data suggest best-in-class potential versus approved small-molecule NK3R antagonists and support advancement to late-stage development.
Key Facts
- Phase 2 trial enrolled 92 postmenopausal women; randomized 1:1 to single 600 mg SC ABCL635 or placebo.
- Mean placebo-adjusted reduction in VMS frequency at week 4: 5.3 events/day (p<0.001); 83% reduction ABCL635 vs 33% placebo.
- Mean placebo-adjusted reduction in VMS severity score at week 4: 1.1 points (p<0.001); 58% reduction ABCL635 vs 12% placebo.
- No serious adverse events or Grade 3+ AEs in the ABCL635 group; headache (28.2%) and fatigue (13.0%) most common AEs.
- 84% of ABCL635 patients rated symptoms as 'Much Better' or 'Moderately Better' on PGI-C vs 27% placebo.
- Significant improvement in sleep disturbance (PROMIS-SD-SF-8b T-score change -5.5 vs placebo, p<0.001).
- Company plans regulatory interactions for late-stage development in VMS due to menopause and oncology treatments.
Financial Impact
Phase 2 success de-risks ABCL635, targeting a $6B+ total addressable market for non-hormonal VMS treatments per management estimates. No financial data in filing.
Risk Factors
- Phase 3 failure or safety issues in larger, longer-duration trials
- Competitive pressure from approved NK3R antagonists (fezolinetant, elinzanetant) and other non-hormonal therapies
- Regulatory delays or additional clinical data requirements
- Cross-trial comparisons are not head-to-head and may not replicate in Phase 3
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001703057-26-000053 |
| Document: abcl635phase2clinicalupd.htm | 0001703057-26-000053 |
| Document: a2026-08x10abcl635phase2.htm | 0001703057-26-000053 |
| Document: 0001703057-26-000053-index-headers.html | 0001703057-26-000053 |
| Document: 0001703057-26-000053-index.html | 0001703057-26-000053 |
| Document: 0001703057-26-000053.txt | 0001703057-26-000053 |
Track record
16 reports on ABCL
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $12.46 Now $11.12 −10.75% settles Feb 8
- Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
- Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
- Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Viewing Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
- Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers